Adios amigos, page-6

I concur with you fully, especially the bit about zero credibility.

However, the Vivagel launches by Aspen and Mundipharma are now outside SPL's control. I remember one poster noted that a worldwide launch was the best approach, but that argument was fatally flawed when half the potential users were put on hold. It was a risk by management that should not, in my opinion, have been taken. We should have revenue (and feedback) from ANZ and Europe by now, and if management think they can duck that responsibly they are wrong. Even, or especially, if they were badly advised.

The other thing I have noticed is that when a target date is met (AZ's patent for AZD0466 and the issue of a licence to ITF for example), it is always at the last possible moment. I would hope the start of clinical trials for irinotecan is much sooner than the 30th of June.